BlackBerry (NASDAQ:BBRY): Canaccord’s global survey indicates weak Z10, Q10, and Q5 sales along with declining B7 legacy sales. The firm said BlackBerry’s smartphone channel inventory appears high and lowered 2014 and 2015 sell-in estimates. Shares remain Sell rated with an $8 price target.
Rigel Pharmaceuticals (NASDAQ:RIGL): Leerink views Rigel Pharmaceuticals as a compelling value buy and reiterates an Outperform rating on the stock with a $5 price target on shares. The firm says that plans to repurpose Fostamatinib for Idiopathic thrombocytopenic purpura was the most likely choice, while R333/R348 represent near-term pipeline catalysts, adding that Rigel has enough cash to last until the second half of 2016.
F5 Networks (NASDAQ:FFIV): After attending F5′s technology open house, Wells Fargo thinks the company’s product sales growth will increase significantly during the next several quarters. The firm believes the increased sales growth may drive the stock higher, and it keeps an Outperform rating on the stock.
Sherwin-Williams (NYSE:SHW): Longbow upgraded Sherwin-Williams to Buy from Neutral. The firm upgraded shares due to expectations for stronger top-line growth, margin expansion, and an expected resolution on Comex, giving a price target of $215.
Don’t Miss: Will BlackBerry Be Cut Free by November?